

A photograph of a snowy mountain range under a starry night sky with a vibrant green aurora borealis. The mountains are covered in snow and have some small buildings at their base. The sky is dark blue with many stars and a bright green aurora borealis. The water in the foreground is calm and reflects the lights.

ArcticZymes Technologies

Shaped by the Arctic

May 2021



Specialist supplier of best-in-class novel enzymes



Innovative Offering

- Novel enzymes technology
- Focus on high-quality, robust manufacturing and reliable supply



B2B and OEM sales

- Broad customer base and long-term commercial relationships
- Serve 3 attractive growth market



Performance

- Profitable & sales rapidly growing
- Forward leaning growth strategy


Our Novel Enzyme Products

Different ways in which enzymes can manipulate DNA, for example:

Therapeutics


Gene therapy & DNA vaccines

- Optimal solution
- Streamlines workflow
- Cost effective



Salt Active Nuclease

Cuts up and destroys DNA



IsoPol™ Polymerase

Amplifies/Copies DNA


Molecular Diagnostics

Viral Based Diagnostics

- Faster sample-to-answer
- Workflow simplified
- Supports simpler instrumentation

Target Markets & Customers

Serving attractive & growing markets



Therapeutics
Gene therapy & DNA vaccine manufacturers



Molecular Research
Research kit manufacturers




Molecular Diagnostics
Commercial diagnostic test developers



Our Customers

ArcticZymes is a trusted critical raw material supply



Our Business Dynamics

- Large volume bulk sales (often >1MNOK orders)
- Economies of scale achieve highest gross margins
- Enzymes are integrated into our customers products or manufacturing processes (long-term business created)

Financials

Q1 2021 Performance

Key Financials


- 119% improvement in sales (MNOK 40.4 vs 18.5)
- 194% improvement in EBITDA (MNOK 25.8 vs 9.0)
- Cash balance MNOK 163.3 (Q1 2020: MNOK 35.7)

Commercial Drivers

- Contribution of total Q1 sales
 - 25% Therapeutics
 - 50% Diagnostics
 - 25% Research

Coronavirus Related Sales


- MNOK 16.5
- 41% contribution of total Q1 sales



Growth Strategy

European's leading one-stop-shop enzyme supplier

Simplified Workflow



- Achieved through building a complete portfolio of enzymes to support any workflow
- Positioned to exploit the whole value chain. Both horizontally and vertically
- Adopting a forward leaning approach via organic and inorganic growth initiatives

Summary

High Growth Business

About leverage existing and new long-term B2B relationships

Accelerate Expansion

Broaden product range:

- Bolt and build via M&A
- Ramp up innovation pipeline & operations

Build Long-Term Shareholder Value

Driven by sustainable profitability and topline growth



Thank you

Q&A Session

Disclaimer

This presentation contains certain forward-looking information and statements. Such forward-looking information and statements are based on the current, estimates and projections of the Company or assumptions based on information currently available to the Company. Such forward-looking information and statements reflect current views with respect to future events and are subject to risks, uncertainties and assumptions. The Company cannot give assurance to the correctness of such information and statements. These forward-looking information and statements can generally be identified by the fact that they do not relate only to historical or current facts.

Forward-looking statements sometimes use terminology such as "targets", "believes", "expects", "aims", "assumes", "intends", "plans", "seeks", "will", "may", "anticipates", "would", "could", "continues", "estimate", "milestone or other words of similar meaning and similar expressions or the negatives thereof. By their nature, forward-looking information and statements involve known and unknown risks, uncertainties and other important factors that could cause the actual results, performance or achievements of the Company to differ materially from any future results, performance or achievements that may be expressed or implied by the forward-looking information and statements in this presentation. Should one or more of these risks or uncertainties materialize, or should any underlying assumptions prove to be incorrect, the Company's actual financial condition or results of operations could differ materially from that or those described herein as anticipated, believed, estimated or expected.

Any forward-looking information or statements in this presentation speak only as at the date of this presentation. Except as required by the Oslo Stock Exchange rules or applicable law, the Company does not intend, and expressly disclaims any obligation or undertaking, to publicly update, correct or revise any of the information included in this presentation, including forward-looking information and statements, whether to reflect changes in the Company's expectations with regard thereto or as a result of new information, future events, changes in conditions or circumstances or otherwise on which any statement in this presentation is based. Given the aforementioned uncertainties, prospective investors are cautioned not to place undue reliance on any of these forward-looking statements.